Enfermedad celíaca silente: explorando el iceberg en población escolar

Pascual, Mercedes; Riechmann, Enriqueta Román; Jimenez, Jennifer; Martín, Manuel; Torres, Joselit; Pascual, Ángel Castaño; Moreno, Óscar; Rincón, A. Fernández

doi:10.1016/s1695-4033(02)77934-4

Cited by 19 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ours is the first study to analyze the prevalence of CD among healthy children followed from birth in Spain. A recent study in Spanish school children observed an overall prevalence of 1:220, whereas another report in the Spanish adult population found a prevalence of 1:389 (24,25).…”

Section: Discussionmentioning

confidence: 90%

Prospective Population Screening for Celiac Disease: High Prevalence in the First 3 Years of Life

Castaño,

Blarduni,

Ortiz

et al. 2004

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Background:Celiac disease (CD) is an autoimmune enteropathy that develops in genetically susceptible individuals exposed to gliadin. Early diagnosis of CD may reduce the risk of complications, and several studies have related the duration of gluten exposure to the risk of other autoimmune diseases. It has been proposed that silent CD be diagnosed as soon as possible to avoid potential complications.Objectives:The purpose of this study was to determine the prevalence of CD among children less than 3 years and to provide treatment to those patients diagnosed with CD.Patients and Methods:Parents of 1100 healthy children born between October 1998 and December 1999 were asked at the time of delivery to enroll their children in a program for the early diagnosis of CD. The parents of 830 children agreed to participate. Patients in the study were examined and anti–tissue transglutaminase antibody was first measured at about 1.5 years of age. A second antibody titer was obtained at about 2.5 years of age. Patients with detectable autoantibodies underwent intestinal biopsy for confirmation of CD.Results:Of the 830 children initially enrolled, 613 and 484 returned for the first and second visits, respectively. None had anti–tissue transglutaminase antibodies at the first visit, but 9 had anti–tissue transglutaminase immunoglobulins at the second visit. In 7 of these 9, intestinal biopsy confirmed the diagnosis of CD which suggests a minimum prevalence of CD of 1 per 118 healthy newborns.Conclusions:The authors observed a very high prevalence of CD, comparable to that observed in other European populations, which might even be higher if all of the children initially examined had returned for their second visit. If general screening for CD were accepted, the authors would recommend age 2–3 years as the best time for measuring tissue transglutaminase antibodies.

show abstract

Section: Discussionmentioning

confidence: 90%

Prospective Population Screening for Celiac Disease: High Prevalence in the First 3 Years of Life

Castaño,

Blarduni,

Ortiz

et al. 2004

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…According to the published data, the prevalence of HLA-DQ2 and DQ8 in the Spanish general population is about 30%[ 8 ]. Therefore, considering a 95% confidence level (type I error of 0.05, and 0.8 statistical power), we needed a sample size of 323 patients to detect significant differences between groups.…”

Section: Methodsmentioning

confidence: 99%

“…CeD is a life-long inflammatory condition of the small intestine represented by a gluten-sensitive enteropathy in genetically susceptible individuals[ 7 ]. CeD has defined diagnostic criteria[ 8 ], which include blood antibodies, genetic testing, upper endoscopy findings and, especially, histological small-bowel changes. The involvement of human leucocyte antigen (HLA) genes codifying HLA-DQ2 and -DQ8 antigens in the susceptibility to the disease is clearly established and HLA typing has been accepted as a useful test to exclude CeD, because only 0.5% of CeD patients lack both DQ2 and DQ8 antigens[ 9 ].…”

Section: Introductionmentioning

confidence: 99%

HLA-DQ: Celiac diseasevsinflammatory bowel disease

Bosca-Watts

Mínguez

Planelles³

et al. 2018

WJG

View full text Add to dashboard Cite

AIMTo determine the genetic predisposition to celiac disease (CeD) in inflammatory bowel disease (IBD) patients by quantifying the frequency of CeD-related human leucocyte antigen (HLA) (HLA-CeD: HLA-DQ2 and -DQ8) in IBD patients globally, by type of IBD and gender, and by calculating the protective/risk contribution of these haplotypes in the development of the IBD disease.METHODSWe conducted a prospective study with IBD patients from our Unit. Clinical information was gathered and blood was tested for HLA-CeD. The control group was made up of unrelated Valencian organ donors.RESULTS1034 subjects were analyzed: 457 IBD [207 ulcerative coliti (UC) and 250 Crohn’s disease (CD)] patients and 577 healthy controls. 39% of the controls and 34% of the patients had HLA-CeD (P = 0.0852). HLA-DQ2 was less frequent in UC patients (P = 0.0287), and HLA-DQ8 in CD (P = 0.0217). In women with UC, the frequency of DQ2.5cis (DQB1*02:01-DQA1*05:01) was reduced ≥ 50% [P = 0.0344; preventive fraction (PF) = 13%]. PFs (7%-14%) were obtained with all HLA-CeD haplotypes. HLA DQB1*02:02-DQA1*02:01 (HLA-DQ2.2) was more frequent in CD patients with respect to controls (P = 0.001) and UC patients (etiological fraction = 15%).CONCLUSIONHLA-CeD is not more frequent in IBD patients, with an even lower frequency of HLA-DQ2 and -DQ8 in UC and CD respectively. HLA-DQ2.5 confers protection from the development of UC, especially in women, and HLA-DQ8 does so for the appearance of CD. HLA-DQ2.2 is present in 34% of the CD patients and may constitute a genetic risk factor for CD development.

show abstract

“…Duplicate and triple publications were eliminated. Thanks to this strategy, 26 studies performed in 17 different countries were found (14–39). The biopsy‐proven prevalence rates of CD provided by the articles were taken into account.…”

Section: Methodsmentioning

confidence: 99%